PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab

References

• The lipid research clinics coronary primary prevention tria results. I. Reduction in incidence of coronary heart diseaseJAMA198425133513646361299
   PubMed Web of Science ®Google Scholar
• The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol loweringJAMA198425133653746361300
   PubMed Web of Science ®Google Scholar
• StamlerJWentworthDNeatonJDIs relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the multiple risk factor intervention trial (MRFIT)JAMA198625620282328283773199
   PubMed Web of Science ®Google Scholar
• WilsonPWD’AgostinoRBLevyDBelangerAMSilbershatzHKannelWBPrediction of coronary heart disease using risk factor categoriesCirculation19989718183718479603539
   PubMed Web of Science ®Google Scholar
• AndersonTJGregoireJHegeleRA2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adultCan J Cardiol201329215116723351925
   PubMed Web of Science ®Google Scholar
• Expert DyslipidemiaPGrundySMAn International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemiaJ Clin Lipidol20137656156524314355
   PubMed Web of Science ®Google Scholar
• PerkJDe BackerGGohlkeHEuropean guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)Eur Heart J201233131635170122555213
   PubMed Web of Science ®Google Scholar
• StoneNJRobinsonJGLichtensteinAH2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesCirculation201412925 suppl 2S1S4524222016
   PubMed Web of Science ®Google Scholar
• CanonCPBlazingMAGiuglianoRPEzetimibe added to statin therapy after acute coronary syndromesN Engl J Med2015372252387239726039521
   PubMed Web of Science ®Google Scholar
• BoekholdtSMHovinghGKMoraSVery low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trialsJ Am Coll Cardiol201464548549425082583
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration; BaigentCBlackwellLEmbersonJEfficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trialsLancet201037697531670168121067804
   PubMed Web of Science ®Google Scholar
• HsiaJMacFadyenJGMonyakJRidkerPMCardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)J Am Coll Cardiol201157161666167521492764
   PubMed Web of Science ®Google Scholar
• WiviottSDCannonCPMorrowDACan low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudyJ Am Coll Cardiol20054681411141616226163
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMKasteleinJJTreating to New Targets (TNT) Steering Committee and InvestigatorsSteering Committee and Investigators. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study)Am J Cardiol2007100574775217719314
   PubMed Web of Science ®Google Scholar
• WatersDDBrotonsCChiangCWLipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goalsCirculation20091201283419546386
   PubMed Web of Science ®Google Scholar
• BruckertEHayemGDejagerSYauCBegaudBMild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO studyCardiovasc Drugs Ther200519640341416453090
   PubMed Web of Science ®Google Scholar
• EllisJJEricksonSRStevensonJGBernsteinSJStilesRAFendrickAMSuboptimal statin adherence and discontinuation in primary and secondary prevention populationsJ Gen Intern Med200419663864515209602
   PubMed Web of Science ®Google Scholar
• EricksonSRLinYNGeospatial analysis of statin adherence using pharmacy claims data in the state of MichiganJ Manag Care Spec Pharm201420121208121525443514
   PubMed Web of Science ®Google Scholar
• AvornJMonetteJLacourAPersistence of use of lipid-lowering medications: a cross-national studyJAMA199827918145814629600480
   PubMed Web of Science ®Google Scholar
• AbifadelMVarretMRabesJPMutations in PCSK9 cause autosomal dominant hypercholesterolemiaNat Genet200334215415612730697
   PubMed Web of Science ®Google Scholar
• BrowningJDHortonJDFasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humansJ Lipid Res201051113359336320716520
   PubMed Web of Science ®Google Scholar
• PerssonLCaoGStahleLCirculating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humansArterioscler Thromb Vasc Biol201030122666267220884874
   PubMed Web of Science ®Google Scholar
• SeidahNGBenjannetSWickhamLThe secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiationProc Natl Acad Sci U S A2003100392893312552133
   PubMed Web of Science ®Google Scholar
• AbifadelMRabesJPDevillersMMutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and diseaseHum Mutat200930452052919191301
   PubMed Web of Science ®Google Scholar
• CohenJPertsemlidisAKotowskiIKGrahamRGarciaCKHobbsHHLow LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9Nat Genet200537216116515654334
   PubMed Web of Science ®Google Scholar
• CohenJCBoerwinkleEMosleyTHJrHobbsHHSequence variations in PCSK9, low LDL, and protection against coronary heart diseaseN Engl J Med2006354121264127216554528
   PubMed Web of Science ®Google Scholar
• LopezDPCSK9: an enigmatic proteaseBiochim Biophys Acta20081781418419118280815
   PubMed Web of Science ®Google Scholar
• DubucGChamberlandAWassefHStatins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemiaArterioscler Thromb Vasc Biol20042481454145915178557
   PubMed Web of Science ®Google Scholar
• DunnKWMcGrawTEMaxfieldFRIterative fractionation of recycling receptors from lysosomally destined ligands in an early sorting endosomeJ Cell Biol19891096 pt 2330333142600137
   PubMed Web of Science ®Google Scholar
• ZhangDWLagaceTAGarutiRBinding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradationJ Biol Chem200728225186021861217452316
   PubMed Web of Science ®Google Scholar
• ChanJCPiperDECaoQA proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primatesProc Natl Acad Sci U S A2009106249820982519443683
   PubMed Web of Science ®Google Scholar
• LiangHChaparro-RiggersJStropPProprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primatesJ Pharmacol Exp Ther2012340222823622019884
   PubMed Web of Science ®Google Scholar
• MurphyKTraversPWalportMJaneway’s ImmunobiologySeventh edNew York, NYGarland Science, Taylor & Francis Group2008
   Google Scholar
• LoboEDHansenRJBalthasarJPAntibody pharmacokinetics and pharmacodynamicsJ Pharm Sci200493112645266815389672
   PubMed Web of Science ®Google Scholar
• TabriziMATsengCMRoskosLKElimination mechanisms of therapeutic monoclonal antibodiesDrug Discov Today2006111–2818816478695
   PubMed Web of Science ®Google Scholar
• WeinerLMFully human therapeutic monoclonal antibodiesJ Immunother20062911916365595
   PubMed Web of Science ®Google Scholar
• YangXDJiaXCCorvalanJRWangPDavisCGDevelopment of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapyCrit Rev Oncol Hematol2001381172311255078
   PubMed Web of Science ®Google Scholar
• HwangWYFooteJImmunogenicity of engineered antibodiesMethods200536131015848070
   PubMed Web of Science ®Google Scholar
• LonbergNHuman antibodies from transgenic animalsNat Biotechnol20052391117112516151405
   PubMed Web of Science ®Google Scholar
• LonbergNFully human antibodies from transgenic mouse and phage display platformsCurr Opin Immunol200820445045918606226
   PubMed Web of Science ®Google Scholar
• McKenneyJMKorenMJKereiakesDJHanotinCFerrandACSteinEASafety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapyJ Am Coll Cardiol201259252344235322463922
   PubMed Web of Science ®Google Scholar
• PRALUENT (alirocumab) [package insert]Bridgewater, NJSanofi-Aventis U.S. LLC2015
   Google Scholar
• REPATHA (evolocumab) [package insert]Thousand Oaks, CAAmgen, Inc2015
   Google Scholar
• BlomDJHalaTBologneseMA 52-week placebo-controlled trial of evolocumab in hyperlipidemiaN Engl J Med2014370191809181924678979
   PubMed Web of Science ®Google Scholar
• KorenMJLundqvistPBologneseMAnti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumabJ Am Coll Cardiol201463232531254024691094
   PubMed Web of Science ®Google Scholar
• RaalFJSteinEADufourRPCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialLancet2015385996533134025282519
   PubMed Web of Science ®Google Scholar
• RobinsonJGNedergaardBSRogersWJEffect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trialJAMA2014311181870188224825642
   PubMed Web of Science ®Google Scholar
• StroesEColquhounDSullivanDAnti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumabJ Am Coll Cardiol201463232541254824694531
   PubMed Web of Science ®Google Scholar
• BaysHGaudetDWeissRAlirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trialJ Clin Endocrinol Metab201510083140314826030325
   PubMed Web of Science ®Google Scholar
• CannonCPCariouBBlomDEfficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trialEur Heart J201536191186119425687353
   PubMed Web of Science ®Google Scholar
• KasteleinJJGinsbergHNLangsletGODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemiaEur Heart J201536432996300326330422
   PubMed Web of Science ®Google Scholar
• KereiakesDJRobinsonJGCannonCPEfficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I studyAm Heart J20151696906915e91326027630
   PubMed Web of Science ®Google Scholar
• RobinsonJGFarnierMKrempfMEfficacy and safety of alirocumab in reducing lipids and cardiovascular eventsN Engl J Med2015372161489149925773378
   PubMed Web of Science ®Google Scholar
• RothEMTaskinenMRGinsbergHNMonotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trialInt J Cardiol20141761556125037695
   PubMed Web of Science ®Google Scholar
• MoriartyPMThompsonPDCannonCPEfficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trialJ Clin Lipidol20159675876926687696
   PubMed Web of Science ®Google Scholar
• SabatineMSGiuglianoRPWiviottSDEfficacy and safety of evolocumab in reducing lipids and cardiovascular eventsN Engl J Med2015372161500150925773607
   PubMed Web of Science ®Google Scholar
• Emerging Risk FactorsCErqouSKaptogeSLipoprotein(a) concentration and the risk of coronary heart disease, stroke, and non-vascular mortalityJAMA2009302441242319622820
   PubMed Web of Science ®Google Scholar
• NaveAHLangeKSLeonardsCOLipoprotein (a) as a risk factor for ischemic stroke: a meta-analysisAtherosclerosis2015242249650326298741
   PubMed Web of Science ®Google Scholar
• HaffnerSOrchardTSteinESchmidtDLaBellePEffect of simvastatin on Lp(a) concentrationsClin Cardiol19951852612677628131
   PubMed Web of Science ®Google Scholar
• RaalFJGiuglianoRPSabatineMSReduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trialsJ Am Coll Cardiol201463131278128824509273
   PubMed Web of Science ®Google Scholar
• GoldsteinJLHobbsHHBrownMSFamilial hypercholesterolemiaScriverCRBeaudetALSlyWSValleDThe Metabolic and Molecular Bases of Inherited Disease8th edNew York, NYMcGraw-Hill Inc200128632913
   Google Scholar
• MaraisADRaalFJSteinEAA dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemiaAtherosclerosis2008197140040617727860
   PubMed Web of Science ®Google Scholar
• RaalFJPilcherGJIllingworthDRExpanded-dose simvastatin is effective in homozygous familial hypercholesterolaemiaAtherosclerosis199713522492569430375
   PubMed Web of Science ®Google Scholar
• RaalFJHonarpourNBlomDJInhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trialLancet2015385996534135025282520
   PubMed Web of Science ®Google Scholar
• ArmitageJThe safety of statins in clinical practiceLancet200737096011781179017559928
   PubMed Web of Science ®Google Scholar
• GangaHVSlimHBThompsonPDA systematic review of statin-induced muscle problems in clinical trialsAm Heart J2014168161524952854
   PubMed Web of Science ®Google Scholar
• NewmanCBTobertJAStatin intolerance: reconciling clinical trials and clinical experienceJAMA2015313101011101225756433
   PubMed Web of Science ®Google Scholar
• RosensonRSBakerSKJacobsonTAKopeckySLParkerBAThe National Lipid Association’s Muscle Safety Expert P. An assessment by the statin muscle safety task force: 2014 updateJ Clin Lipidol201483 supplS58S7124793443
   PubMed Web of Science ®Google Scholar
• KorenMJGiuglianoRPRaalFJEfficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trialCirculation2014129223424324255061
   PubMed Web of Science ®Google Scholar
• Rojas-FernandezCHGoldsteinLBLeveyAITaylorBABittnerVThe National Lipid Association’s Safety Task F. An assessment by the statin cognitive safety task force: 2014 updateJ Clin Lipidol201483 supplS5S1624793442
   PubMed Web of Science ®Google Scholar
• SattarNPreissDMurrayHMStatins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsLancet2010375971673574220167359
   PubMed Web of Science ®Google Scholar
• StromBLSchinnarRKarlawishJHennessySTealVBilkerWBStatin therapy and risk of acute memory impairmentJAMA Intern Med201517581399140526054031
   PubMed Web of Science ®Google Scholar
• SimicIReinerZAdverse effects of statins – myths and realityCurr Pharm Des20152191220122625312733
   PubMed Web of Science ®Google Scholar
• KraftRKahnAMedina-FrancoJLA cell-based fascin bioassay identifies compounds with potential anti-metastasis or cognition-enhancing functionsDis Model Mech20136121723522917928
   PubMed Web of Science ®Google Scholar
• BjorkhemIMeaneySBrain cholesterol: long secret life behind a barrierArterioscler Thromb Vasc Biol200424580681514764421
   PubMed Web of Science ®Google Scholar
• KorenMJBlomDGiuglianoRPSafety and tolerability of very low LDL-C levels in patients treated with 52 weeks of evolocumab (AMG 145)Circulation201413016865
   Google Scholar
• HacquebardMCarpentierYAVitamin E: absorption, plasma transport and cell uptakeCurr Opin Clin Nutr Metab Care20058213313815716790
   PubMed Web of Science ®Google Scholar
• HuJZhangZShenWJAzharSCellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormonesNutr Metab (Lond)201074720515451
   PubMed Web of Science ®Google Scholar
• BlomDJDjedjosCSMonsalvoMLEffects of evolocumab on vitamin E and steroid hormone levels. Results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES studyCirc Res201511773174126228031
   PubMed Web of Science ®Google Scholar
• QamarABhattDLEffect of low cholesterol on steroid hormones and vitamin E levels: just a theory or real concern?Circ Res2015117866266426405182
   PubMed Web of Science ®Google Scholar
• StroesESGGuytonJFarnierMEfficacy and safety of different dosing regimens of alirocumab (starting doses of 75 mg every two weeks and 150 mg every four weeks) versus placebo in patients with hypercholesterolemia not treated using statins: the ODYSSEY CHOICE II studyJ Am Coll Cardiol20156510S1370
   Google Scholar
• RothEMRaderDJMoriartyPMA randomized phase 3 trial evaluating alirocumab every four weeks dosing as add-on to statin or as monotherapy: ODYSSEY CHOICE IPresented at: ISA 2015, the 17th International Symposium on AtherosclerosisMay 23–26, 2015Amsterdam2016 Available from: http://www.athero.org/isa2015/ClinicalBreak/Roth.pdfAccessed January 26, 2016
   Google Scholar